0001549595false00015495952025-08-192025-08-19
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
___________________________________________
FORM 8-K
___________________________________________
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported): August 19, 2025
___________________________________________
NURIX THERAPEUTICS, INC.
(Exact Name of Registrant as Specified in its Charter)
___________________________________________
| | | | | | | | |
| Delaware | 001-39398 | 27-0838048 |
(State or Other Jurisdiction of Incorporation or Organization) | (Commission File Number) | (IRS Employer Identification No.) |
| | |
1700 Owens Street, Suite 205 San Francisco, California | | 94158 |
| (Address of Principal Executive Offices) | | (Zip Code) |
(415) 660-5320
(Registrant’s Telephone Number, Including Area Code)
N/A
(Former Name or Former Address, if Changed Since Last Report)
___________________________________________
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| | | | | |
| o | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| |
| o | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| |
| o | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| |
| o | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| | | | | | | | |
| Title of each class | Trading symbol(s) | Name of each exchange on which registered |
| Common Stock, $0.001 par value per share | NRIX | Nasdaq Global Market |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company o
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers..
(b)
On August 19, 2025, Lori A. Kunkel, M.D., advised the board of directors (the “Board”) of Nurix Therapeutics, Inc. (the “Company”) that she would resign as a Class III director of the Board, and as chair of the Clinical and Commercialization Committee of the Board (the "Clinical and Commercialization Committee"), and as a member of the Clinical and Commercialization Committee and the Compensation Committee of the Board, effective September 1, 2025. Dr. Kunkel's decision to resign was not the result of any disagreement with the Company on any matter relating to its operations, policies or practices.
In connection with Dr. Kunkel's resignation, the Board appointed Roy D. Baynes, MB.Bch., M.Med., Ph.D., a member of the Board and the Clinical and Commercialization Committee, to serve as chair of the Clinical and Commercialization Committee, effective as of September 1, 2025.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| | | | | | | | |
| NURIX THERAPEUTICS, INC. |
| | |
Date: August 22, 2025 | By: | /s/ Christine Ring |
| | Christine Ring, Ph.D., J.D. |
| | Chief Legal Officer |
